Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [31] Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients
    Mohamed O. Saad
    Adham M. Mohamed
    Hassan A. Mitwally
    Ahmed A. Shible
    Ali Ait Hssain
    Mohamed A. Abdelaty
    Infection, 2020, 48 : 741 - 747
  • [32] Comparison of acute kidney injury in patients prescribed vancomycin in combination with piperacillin-tazobactam or cefepime for diabetic foot infections
    Piccuirro, Sarah R.
    Casapao, Anthony M.
    Claudio, Alyssa M.
    Isache, Carmen
    Jankowski, Christopher A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (04) : 893 - 896
  • [33] Evaluation of the risk of acute kidney injury with the use of piperacillin/tazobactam among adult critically ill patients
    Saad, Mohamed O.
    Mohamed, Adham M.
    Mitwally, Hassan A.
    Shible, Ahmed A.
    Hssain, Ali Ait
    Abdelaty, Mohamed A.
    INFECTION, 2020, 48 (05) : 741 - 747
  • [34] Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study
    Yamashita, Yuma
    Kawaguchi, Hiroshi
    Yano, Tsubasa
    Sakurai, Norihiro
    Shibata, Wataru
    Oshima, Kazuhiro
    Imai, Takumi
    Yamada, Koichi
    Nakamura, Yasutaka
    Nagayama, Katsuya
    Kakeya, Hiroshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (11) : 1614 - 1620
  • [35] Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients
    Buhlinger, Kaitlyn M.
    Fuller, Kathryn A.
    Faircloth, Cassidy B.
    Wallace, Jessica R.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (16) : 1204 - 1210
  • [36] Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER
    Ide, Naohito
    Sako, Ken-Ichi
    Takigawa, Masaki
    Tanaka, Hiroyuki
    IN VIVO, 2024, 38 (03): : 1436 - 1442
  • [37] Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients
    Kumta, Nilesh
    Heffernan, Aaron J.
    Cotta, Menino Osbert
    Liu, Xin
    Parker, Suzanne
    Wallis, Steven
    Livermore, Amelia
    Starr, Therese
    Wong, Wai Tat
    Joynt, Gavin M.
    Lipman, Jeffrey
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (02)
  • [38] Concomitant vancomycin and piperacillin/tazobactam treatment is associated with an increased risk of acute kidney injury in Japanese patients
    Haruki, Yuto
    Hagiya, Hideharu
    Haruki, Mai
    Inoue, Yuta
    Sugiyama, Tetsuhiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2020, 26 (10) : 1026 - 1032
  • [39] The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients With Obesity
    Wuerger, Angela
    Bowden, Jarred
    Mitchell, Anna
    Marler, Jacob
    HOSPITAL PHARMACY, 2023, 58 (06) : 605 - 613
  • [40] The association of high Vancomycin trough concentration with acute kidney injury during combination therapy of Piperacillin/Tazobactam and Vancomycin
    Saito, Syuichiro
    Sugimoto, Takeshi
    Takenaka, Kei
    Goto, Hideaki
    Kumahara, Akira
    Watanabe, Rikiya
    Sugiyama, Daisuke
    Yasutomo, Yoshiro
    Takatsuki, Kiyonobu
    PRACTICAL LABORATORY MEDICINE, 2022, 29